JPMorgan raised the firm’s price target on HCA Healthcare to $332 from $327 and keeps a Neutral rating on the shares. The firm believes diversified managed care organizations and hospitals remain best positioned within its large cap coverage universe. Within managed care, a more defensive approach is still the best way to play the group over the near-term, the analyst tells investors in a research note. JPMorgan remains more cautious on Medicare Advantage given lack of visibility on 2024 cost trends and uncertainty around 2025 bids.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare SVP Torres sells 1,863 common shares
- Appaloosa takes new positions in Adobe and Boeing, boosts Alibaba stake
- HCA Healthcare initiated with a Buy at DBS Bank
- HCA Healthcare CFO Retires, New Directors Elected, Proposals Voted
- HCA Healthcare price target lowered to $360 from $371 at TD Cowen